EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

99m TcPSMA ‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial

Lotte G Zuur iD, Hilda A de Barros iD, Matthias N van Oosterom, Anne-Claire Berrens, Maarten L Donswijk, Jeroen J M A Hendrikx, Elise M Bekers, André N Vis, Esther M Wit, Fijs B van Leeuwen, Henk G van der Poel iD, Pim J van Leeuwen

BJU International · 2024

DOI: 10.1111/bju.16297 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2024. Verfasst von Lotte G Zuur und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Netherlands Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate whether combination treatment of prostate‐specific membrane antigen (PSMA)‐based radioguided surgery (RGS) with short‐term androgen deprivation therapy (ADT) improves oncological outcomes in men with oligorecurrent prostate cancer (PCa) as compared to treatment with short‐term ADT only.

Methods

The TRACE‐II study is an investigator‐initiated, prospective, randomised controlled clinical trial. Patients (aged >18 years) with hormone‐sensitive recurrent PCa after radical prostatectomy or radiotherapy (brachytherapy or external beam radiotherapy), with involvement of ≤2 lymph nodes or local oligorecurrent disease within the pelvis as determined by PSMA positron emission tomography (PET)/computed tomography (CT) are randomly assigned in a 1:1 ratio between 6‐month ADT (Arm A) or 6‐month ADT plus RGS (Arm B). The primary objective is to determine clinical progression‐free survival (CPFS) at 24 months. After PSMA‐RGS, CPFS is defined as the time between the start of treatment and the appearance of a re‐recurrence (any N1 or M1) as suggested by PSMA‐PET/CT or symptoms related to progressive PCa, or death from any cause. The secondary objectives include metastasis‐free survival at 2, 5 and 10 years, biochemical progression‐free survival at 2 years, and patient‐reported quality of life at 2, 5 and 10 years. A total of 60 patients, 30 per arm, will be included. The trial is powered (80%) to detect at least a 30% absolute difference in CPFS between the two study arms in the period 2 years after randomisation. We expect to enrol the required participants in 3 years. The study has an expected duration of 5 years in total.

Conclusions

Combining RGS with short‐term ADT might be oncologically beneficial for patients with oligorecurrent PCa. In this first randomised controlled trial, we are investigating the potential oncological benefits of this combined treatment, while also focusing on maintaining quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalProstatic NeoplasmsAgedHumansMaleMiddle AgedAndrogen AntagonistsGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProspective StudiesProstatectomyRadiopharmaceuticalsSurgery, Computer-Assisted

Stichwörter der Autor:innen

99mTcPSMAandrogen deprivation therapyoligorecurrentprostate cancerprostate specific membrane antigenradioguided surgery

Substanzen

Androgen AntagonistsGlutamate Carboxypeptidase IIRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Netherlands Prostate Cancer Network, Amsterdam, The Netherlands.
  • Department of Radiology, Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Leiden, The Netherlands.
  • Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Department of Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

ORCID-Profile: Lotte G Zuur, Hilda A de Barros, Henk G van der Poel

Förderung

  • Netherlands Cancer Institute

Zitieren

APA

Zuur, L. G., de Barros, H. A., van Oosterom, M. N., Berrens, A. C., Donswijk, M. L., Hendrikx, J. J. M. A., Bekers, E. M., Vis, A. N., Wit, E. M., van Leeuwen, F. B., van der Poel, H. G., & van Leeuwen, P. J. (2024). 99m TcPSMA ‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial. BJU International. https://doi.org/10.1111/bju.16297

Vancouver

Zuur LG, de Barros HA, van Oosterom MN, Berrens AC, Donswijk ML, Hendrikx JJMA, et al. 99m TcPSMA ‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial. BJU International. 2024. doi:10.1111/bju.16297

BibTeX
@article{Zuur2024,
  author = {Zuur, Lotte G and de Barros, Hilda A and van Oosterom, Matthias N and Berrens, Anne-Claire and Donswijk, Maarten L and Hendrikx, Jeroen J M A and Bekers, Elise M and Vis, André N and Wit, Esther M and van Leeuwen, Fijs B and van der Poel, Henk G and van Leeuwen, Pim J},
  title = {99m TcPSMA ‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16297}
}
Kostenlos starten →